Stay Alert for Safety Issues With Janus Kinase Inhibitors (Xeljanz, etc)

October 2019

Questions will pop up about the safety of Janus kinase (JAK) inhibitors...Xeljanz, Xeljanz XR, and Olumiant.

There's an uptick in the use of JAK inhibitors for rheumatoid arthritis and other autoimmune diseases...because they're oral.

But these specialty meds may fly under your radar if patients don't fill them at your pharmacy.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Influenza Share the Latest Advice About 2019-2020 Influenza Immunizations
E-Cigarettes Emphasize Risks of Vaping and Help Kids and Teens Stop
Anticoagulants Help Manage Direct Oral Anticoagulants Around Surgery
Pediatrics Weigh Options for Managing Type 2 Diabetes in Kids
Practice Demystify the Ins and Outs of Compression Stockings
Crohn's Disease Be Prepared to Discuss Treatment Options for Crohn's Disease in Kids
Vaccines Know When to Discuss HPV Vaccination With Adults Over Age 26
Renal & Urology Be Familiar With Nuances for Managing Neurogenic Bladder
Natural Medicines Tell Patients Not to Rely on Diabasens for Neuropathic Pain
Immunosuppressives Stay Alert for Safety Issues With Janus Kinase Inhibitors (Xeljanz, etc)